Oncology · Phase 2-3 · pulled 2026-11-06

Gastric cancer: trial sites and investigators

25 sites and 10 investigators from 246 completed and terminated Phase 2-3 trials of gastric cancer (last 12 years), plus 300 trials recruiting now.

A cited data summary, not a recommendation to select or exclude any site. Every line links to the registry record behind it.

Sites

Sites are listed in the registry's own order: comparable trials listed (most first), ties by latest completion, then name. The Sitecite score is a second column. “Competing now” counts recruiting, active and not-yet-recruiting trials in the same indication at that site.

Gastric cancer: sites in the registry's trial-count order, with the Sitecite score as a second column
#	Site	Comparable trials listed	Trials (ClinicalTrials.gov)	Latest completion	Competing now	Score (0-100)
1	Severance Hospital, Yonsei University Health System Seoul, South Korea · 31 spellings merged	34 28 completed, 6 terminated	NCT04868877 NCT05002127 NCT05052801 6 trials with titles NCT04868877 Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination terminated 2026-10-01 Stop reason on the record: “The Sponsor terminated the trial early for strategic business reasons. This isn't related to any safety/efficacy/clinical activity/benefit-risk concern with petosemtamab. Ongoing participants will hav” NCT05002127 A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06) completed 2026-06-30 NCT05052801 Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression completed 2026-04-26 NCT05322577 A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer. terminated 2025-11-21 Stop reason on the record: “Sponsor Decision” NCT03615326 Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811) completed 2025-11-12 NCT05111626 Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer. terminated 2025-10-29 Stop reason on the record: “Study was terminated by sponsor”	2026-10-01	21 NCT04198766 NCT07221149 NCT06760819 NCT04421820	94
2	Asan Medical Center Seoul, South Korea · 9 spellings merged	32 24 completed, 8 terminated	NCT05002127 NCT05052801 NCT05322577 6 trials with titles NCT05002127 A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06) completed 2026-06-30 NCT05052801 Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression completed 2026-04-26 NCT05322577 A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer. terminated 2025-11-21 Stop reason on the record: “Sponsor Decision” NCT03615326 Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811) completed 2025-11-12 NCT05111626 Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer. terminated 2025-10-29 Stop reason on the record: “Study was terminated by sponsor” NCT03929666 A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer completed 2025-08-30	2026-06-30	22 NCT04198766 NCT07221149 NCT07149090 NCT06760819	86
3	Samsung Medical Center Seoul, South Korea · 5 spellings merged	30 21 completed, 9 terminated	NCT04868877 NCT05002127 NCT05052801 6 trials with titles NCT04868877 Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination terminated 2026-10-01 Stop reason on the record: “The Sponsor terminated the trial early for strategic business reasons. This isn't related to any safety/efficacy/clinical activity/benefit-risk concern with petosemtamab. Ongoing participants will hav” NCT05002127 A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06) completed 2026-06-30 NCT05052801 Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression completed 2026-04-26 NCT05322577 A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer. terminated 2025-11-21 Stop reason on the record: “Sponsor Decision” NCT03615326 Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811) completed 2025-11-12 NCT05111626 Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer. terminated 2025-10-29 Stop reason on the record: “Study was terminated by sponsor”	2026-10-01	21 NCT07221149 NCT06760819 NCT07911280 NCT05086692	85
4	MD Anderson Cancer Center Houston, United States · 15 spellings merged	25 12 completed, 13 terminated	NCT03615326 NCT05111626 NCT03929666 6 trials with titles NCT03615326 Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811) completed 2025-11-12 NCT05111626 Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer. terminated 2025-10-29 Stop reason on the record: “Study was terminated by sponsor” NCT03929666 A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer completed 2025-08-30 NCT02611024 Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors completed 2025-07-01 NCT04902872 Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors completed 2025-06-24 NCT05572684 A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors terminated 2025-04-30 Stop reason on the record: “Following completion of Phase 1b, the Sponsor decided not to initiate Part 2 of the trial.”	2025-11-12	28 NCT07221149 NCT06760819 NCT06695845 NCT05086692	85
5	Seoul National University Hospital Seoul, South Korea · 7 spellings merged	23 17 completed, 6 terminated	NCT04868877 NCT05002127 NCT05052801 6 trials with titles NCT04868877 Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination terminated 2026-10-01 Stop reason on the record: “The Sponsor terminated the trial early for strategic business reasons. This isn't related to any safety/efficacy/clinical activity/benefit-risk concern with petosemtamab. Ongoing participants will hav” NCT05002127 A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06) completed 2026-06-30 NCT05052801 Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression completed 2026-04-26 NCT05322577 A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer. terminated 2025-11-21 Stop reason on the record: “Sponsor Decision” NCT03615326 Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811) completed 2025-11-12 NCT05111626 Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer. terminated 2025-10-29 Stop reason on the record: “Study was terminated by sponsor”	2026-10-01	17 NCT07221149 NCT06695845 NCT05086692 NCT04421820	84
6	Memorial Sloan Kettering Cancer Center New York, United States · 19 spellings merged	23 11 completed, 12 terminated	NCT03615326 NCT05111626 NCT03929666 6 trials with titles NCT03615326 Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811) completed 2025-11-12 NCT05111626 Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer. terminated 2025-10-29 Stop reason on the record: “Study was terminated by sponsor” NCT03929666 A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer completed 2025-08-30 NCT05007106 MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) completed 2025-08-05 NCT05641896 Study of [18F]FAPI-74 PET in Patients With Gastrointestinal Cancers completed 2025-06-30 NCT03221426 Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) completed 2025-04-23	2025-11-12	28 NCT07221149 NCT06695845 NCT03526835 NCT07262619	77
7	Beijing Cancer Hospital Beijing, China · 23 spellings merged	20 16 completed, 4 terminated	NCT04661150 NCT05052801 NCT05173142 6 trials with titles NCT04661150 A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction completed 2026-07-27 NCT05052801 Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression completed 2026-04-26 NCT05173142 A Phase Ib/II Clinical Study Evaluating HMPL-453 Tartrate as Monotherapy and in Combination With Chemotherapy or Toripalimab in Advanced Solid Tumors completed 2026-01-17 NCT03615326 Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811) completed 2025-11-12 NCT04882241 Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension completed 2025-04-23 NCT03221426 Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) completed 2025-04-23	2026-07-27	30 NCT04556253 NCT07221149 NCT06760819 NCT07518147	91
8	University of Chicago Chicago, United States · 10 spellings merged	18 11 completed, 7 terminated	NCT05111626 NCT03929666 NCT03221426 6 trials with titles NCT05111626 Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer. terminated 2025-10-29 Stop reason on the record: “Study was terminated by sponsor” NCT03929666 A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer completed 2025-08-30 NCT03221426 Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) completed 2025-04-23 NCT04363801 A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer terminated 2025-03-31 Stop reason on the record: “experimental treatment will not be more efficacious than its comparator in the primary endpoint of PFS” NCT04082364 Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer completed 2025-03-25 NCT04278144 A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors terminated 2025-02-14 Stop reason on the record: “Sponsor Decision”	2025-10-29	15 NCT04198766 NCT05677490 NCT06203600 NCT06172478	78
9	Sarah Cannon Research Institute Nashville, United States · 20 spellings merged	17 10 completed, 7 terminated	NCT04868877 NCT05708950 NCT05111626 6 trials with titles NCT04868877 Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination terminated 2026-10-01 Stop reason on the record: “The Sponsor terminated the trial early for strategic business reasons. This isn't related to any safety/efficacy/clinical activity/benefit-risk concern with petosemtamab. Ongoing participants will hav” NCT05708950 A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101) completed 2025-12-18 NCT05111626 Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer. terminated 2025-10-29 Stop reason on the record: “Study was terminated by sponsor” NCT03929666 A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer completed 2025-08-30 NCT04082364 Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer completed 2025-03-25 NCT05070247 A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors terminated 2025-01-06 Stop reason on the record: “Clinical Futility of TAK 500 met. No further development with this compound”	2026-10-01	20 NCT07221149 NCT06760819 NCT06695845 NCT03526835	83
10	City of Hope Duarte, United States · 14 spellings merged	17 11 completed, 6 terminated	NCT03641313 NCT05111626 NCT03008278 6 trials with titles NCT03641313 Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer completed 2026-09-14 NCT05111626 Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer. terminated 2025-10-29 Stop reason on the record: “Study was terminated by sponsor” NCT03008278 Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery completed 2025-08-13 NCT05007106 MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) completed 2025-08-05 NCT03221426 Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) completed 2025-04-23 NCT04363801 A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer terminated 2025-03-31 Stop reason on the record: “experimental treatment will not be more efficacious than its comparator in the primary endpoint of PFS”	2026-09-14	14 NCT04198766 NCT06760819 NCT06172478 NCT02465060	89
11	Fudan University Shanghai Cancer Center Shanghai, China · 21 spellings merged	17 11 completed, 6 terminated	NCT03399110 NCT04661150 NCT05052801 6 trials with titles NCT03399110 XELOX for 4 Months Versus 6 Months in Gastric Cancer (LOMAC) completed 2026-08-15 NCT04661150 A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction completed 2026-07-27 NCT05052801 Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression completed 2026-04-26 NCT03615326 Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811) completed 2025-11-12 NCT05111626 Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer. terminated 2025-10-29 Stop reason on the record: “Study was terminated by sponsor” NCT04082364 Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer completed 2025-03-25	2026-08-15	23 NCT06760819 NCT05152147 NCT07789184 NCT06914687	84
12	Hospital Universitario Ramon y Cajal Madrid, Spain · 10 spellings merged	16 11 completed, 5 terminated	NCT05002127 NCT03615326 NCT05111626 6 trials with titles NCT05002127 A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06) completed 2026-06-30 NCT03615326 Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811) completed 2025-11-12 NCT05111626 Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer. terminated 2025-10-29 Stop reason on the record: “Study was terminated by sponsor” NCT05007106 MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) completed 2025-08-05 NCT02611024 Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors completed 2025-07-01 NCT04278144 A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors terminated 2025-02-14 Stop reason on the record: “Sponsor Decision”	2026-06-30	6 NCT06695845 NCT05086692 NCT06172478 NCT06710132	83
13	Hospital Universitari Vall d'Hebron Barcelona, Spain · 17 spellings merged	15 9 completed, 6 terminated	NCT04868877 NCT05002127 NCT02611024 6 trials with titles NCT04868877 Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination terminated 2026-10-01 Stop reason on the record: “The Sponsor terminated the trial early for strategic business reasons. This isn't related to any safety/efficacy/clinical activity/benefit-risk concern with petosemtamab. Ongoing participants will hav” NCT05002127 A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06) completed 2026-06-30 NCT02611024 Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors completed 2025-07-01 NCT04278144 A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors terminated 2025-02-14 Stop reason on the record: “Sponsor Decision” NCT02205047 Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma completed 2024-12-31 NCT04189445 Futibatinib in Patients With Specific FGFR Aberrations terminated 2024-11-11 Stop reason on the record: “Sponsor made a strategic decision to terminate the study considering enrollment challenges for some of the cohorts in the trial.”	2026-10-01	13 NCT06695845 NCT03526835 NCT06172478 NCT06710132	79
14	UCLA Los Angeles, United States · 12 spellings merged	15 8 completed, 7 terminated	NCT05002127 NCT05052801 NCT05111626 6 trials with titles NCT05002127 A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06) completed 2026-06-30 NCT05052801 Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression completed 2026-04-26 NCT05111626 Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer. terminated 2025-10-29 Stop reason on the record: “Study was terminated by sponsor” NCT05641896 Study of [18F]FAPI-74 PET in Patients With Gastrointestinal Cancers completed 2025-06-30 NCT05563272 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors terminated 2025-05-09 Stop reason on the record: “Indication scouting for TLX250-CDx will continue in theranostic studies, with a therapeutic component in the study design.” NCT04363801 A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer terminated 2025-03-31 Stop reason on the record: “experimental treatment will not be more efficacious than its comparator in the primary endpoint of PFS”	2026-06-30	3 NCT07217704 NCT07700979 NCT07101666	76
15	Institut Gustave Roussy Villejuif, France · 11 spellings merged	15 10 completed, 5 terminated	NCT05052801 NCT03615326 NCT05111626 6 trials with titles NCT05052801 Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression completed 2026-04-26 NCT03615326 Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811) completed 2025-11-12 NCT05111626 Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer. terminated 2025-10-29 Stop reason on the record: “Study was terminated by sponsor” NCT05007106 MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) completed 2025-08-05 NCT02611024 Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors completed 2025-07-01 NCT03675737 Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859) completed 2025-03-03	2026-04-26	9 NCT06760819 NCT06172478 NCT06710132 NCT06427941	88
16	Dana Farber Cancer Institute Boston, United States · 4 spellings merged	15 8 completed, 7 terminated	NCT03615326 NCT03008278 NCT04363801 6 trials with titles NCT03615326 Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811) completed 2025-11-12 NCT03008278 Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery completed 2025-08-13 NCT04363801 A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer terminated 2025-03-31 Stop reason on the record: “experimental treatment will not be more efficacious than its comparator in the primary endpoint of PFS” NCT04278144 A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors terminated 2025-02-14 Stop reason on the record: “Sponsor Decision” NCT05070247 A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors terminated 2025-01-06 Stop reason on the record: “Clinical Futility of TAK 500 met. No further development with this compound” NCT04727151 TAC T-cells for the Treatment of HER2-positive Solid Tumors terminated 2024-03-25 Stop reason on the record: “Study terminated by Sponsor for commercial reasons”	2025-11-12	14 NCT06760819 NCT05677490 NCT02465060 NCT03504397	83
17	Korea University Anam Hospital Seoul, South Korea · 3 spellings merged	14 12 completed, 2 terminated	NCT05002127 NCT05052801 NCT05111626 6 trials with titles NCT05002127 A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06) completed 2026-06-30 NCT05052801 Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression completed 2026-04-26 NCT05111626 Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer. terminated 2025-10-29 Stop reason on the record: “Study was terminated by sponsor” NCT03929666 A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer completed 2025-08-30 NCT03221426 Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) completed 2025-04-23 NCT04363801 A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer terminated 2025-03-31 Stop reason on the record: “experimental treatment will not be more efficacious than its comparator in the primary endpoint of PFS”	2026-06-30	8 NCT04198766 NCT07262619 NCT05152147 NCT05523947	87
18	The Christie NHS Foundation Trust Manchester, United Kingdom · 9 spellings merged	14 11 completed, 3 terminated	NCT03615326 NCT05111626 NCT05714553 6 trials with titles NCT03615326 Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811) completed 2025-11-12 NCT05111626 Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer. terminated 2025-10-29 Stop reason on the record: “Study was terminated by sponsor” NCT05714553 NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours terminated 2025-05-30 Stop reason on the record: “The NuTide:303 study was terminated at NuCana's discretion following refinement of the NUC-3373 development strategy.” NCT03221426 Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) completed 2025-04-23 NCT04082364 Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer completed 2025-03-25 NCT02205047 Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma completed 2024-12-31	2025-11-12	10 NCT07221149 NCT04180371 NCT07070232 NCT05944237	87
19	Fondazione IRCCS Istituto Nazionale dei Tumori Milan, Italy · 11 spellings merged	13 10 completed, 3 terminated	NCT04868877 NCT05002127 NCT05111626 6 trials with titles NCT04868877 Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination terminated 2026-10-01 Stop reason on the record: “The Sponsor terminated the trial early for strategic business reasons. This isn't related to any safety/efficacy/clinical activity/benefit-risk concern with petosemtamab. Ongoing participants will hav” NCT05002127 A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06) completed 2026-06-30 NCT05111626 Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer. terminated 2025-10-29 Stop reason on the record: “Study was terminated by sponsor” NCT03221426 Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) completed 2025-04-23 NCT03675737 Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859) completed 2025-03-03 NCT04014075 DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02) completed 2024-02-13	2026-10-01	12 NCT07221149 NCT06760819 NCT04421820 NCT06710132	87
20	Centre Léon Bérard Lyon, France · 8 spellings merged	13 11 completed, 2 terminated	NCT05002127 NCT05052801 NCT03615326 6 trials with titles NCT05002127 A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06) completed 2026-06-30 NCT05052801 Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression completed 2026-04-26 NCT03615326 Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811) completed 2025-11-12 NCT05111626 Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer. terminated 2025-10-29 Stop reason on the record: “Study was terminated by sponsor” NCT05007106 MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) completed 2025-08-05 NCT02611024 Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors completed 2025-07-01	2026-06-30	7 NCT03526835 NCT06172478 NCT05152147 NCT06128551	88
21	Korea University Guro Hospital Seoul, South Korea · 2 spellings merged	13 10 completed, 3 terminated	NCT05002127 NCT05052801 NCT05322577 6 trials with titles NCT05002127 A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06) completed 2026-06-30 NCT05052801 Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression completed 2026-04-26 NCT05322577 A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer. terminated 2025-11-21 Stop reason on the record: “Sponsor Decision” NCT05111626 Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer. terminated 2025-10-29 Stop reason on the record: “Study was terminated by sponsor” NCT04363801 A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer terminated 2025-03-31 Stop reason on the record: “experimental treatment will not be more efficacious than its comparator in the primary endpoint of PFS” NCT04082364 Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer completed 2025-03-25	2026-06-30	7 NCT04198766 NCT06710132 NCT05152147 NCT05144854	79
22	National Taiwan University Hospital Taipei, Taiwan · 10 spellings merged	13 10 completed, 3 terminated	NCT05002127 NCT05322577 NCT05007106 6 trials with titles NCT05002127 A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06) completed 2026-06-30 NCT05322577 A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer. terminated 2025-11-21 Stop reason on the record: “Sponsor Decision” NCT05007106 MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) completed 2025-08-05 NCT03221426 Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) completed 2025-04-23 NCT04082364 Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer completed 2025-03-25 NCT03675737 Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859) completed 2025-03-03	2026-06-30	9 NCT06172478 NCT07392892 NCT05150691 NCT06731478	84
23	National Cheng Kung University Hospital Tainan, Taiwan · 6 spellings merged	12 10 completed, 2 terminated	NCT05002127 NCT05052801 NCT05111626 6 trials with titles NCT05002127 A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06) completed 2026-06-30 NCT05052801 Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression completed 2026-04-26 NCT05111626 Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer. terminated 2025-10-29 Stop reason on the record: “Study was terminated by sponsor” NCT03221426 Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) completed 2025-04-23 NCT03675737 Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859) completed 2025-03-03 NCT04276493 Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab completed 2024-10-31	2026-06-30	8 NCT04198766 NCT06172478 NCT07392892 NCT06731478	85
24	Washington University School of Medicine St Louis, United States · 18 spellings merged	12 9 completed, 3 terminated	NCT03615326 NCT04082364 NCT04162665 6 trials with titles NCT03615326 Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811) completed 2025-11-12 NCT04082364 Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer completed 2025-03-25 NCT04162665 Pre-operative Adaptive Short Court Radiation Therapy in Gastric Cancer terminated 2024-11-21 Stop reason on the record: “Poor accrual and funding sponsor declared bankruptcy.” NCT04014075 DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02) completed 2024-02-13 NCT05012397 Milademetan in Advanced/Metastatic Solid Tumors terminated 2023-10-15 Stop reason on the record: “Sponsor Decision” NCT04208958 Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer completed 2023-02-23	2025-11-12	17 NCT04198766 NCT03526835 NCT06203600 NCT06172478	86
25	Yale University New Haven, United States · 8 spellings merged	12 9 completed, 3 terminated	NCT05111626 NCT03008278 NCT04902872 6 trials with titles NCT05111626 Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer. terminated 2025-10-29 Stop reason on the record: “Study was terminated by sponsor” NCT03008278 Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery completed 2025-08-13 NCT04902872 Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors completed 2025-06-24 NCT03221426 Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) completed 2025-04-23 NCT04082364 Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer completed 2025-03-25 NCT05259696 Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01) completed 2024-10-24	2025-10-29	11 NCT06901531 NCT06203600 NCT06172478 NCT02465060	94

Investigators

Principal investigators and study chairs of the comparable trials, most trials first. Papers are matched on name, affiliation and condition; the match confidence is shown on each.

Gastric cancer: principal investigators and study chairs of the comparable trials, with matched papers
#	Investigator	Comparable trials	Trials (ClinicalTrials.gov)	Papers (PubMed)
1	Sun Young RHA Yonsei Cancer Center, Severance Hospital, Yonsei University College of Medicine	5	NCT04835896 NCT05400915 NCT05529667 NCT05535569 NCT02501603	PMID 42919242 BMC cancer, 2026 · High match PMID 42786305 Nature medicine, 2026 · High match PMID 42784857 European journal of oncology nursing : the official journal of European Oncology Nursing Society, 2026 · High match
2	James C Yang National Cancer Institute (NCI)	5	NCT03745326 NCT03648879 NCT03606928 NCT03092518 NCT03104283	PMID 33236884 ACS applied materials & interfaces, 2021 · Medium match
3	Jeeyun Lee Samsung Medical Center	4	NCT05419362 NCT03170180 NCT03052478 NCT03061708	No paper matched at High or Medium confidence
4	Andrew Blakely National Cancer Institute (NCI)	3	NCT04535414 NCT04034251 NCT03607656	No paper matched at High or Medium confidence
5	Hyun Kim Washington University School of Medicine	3	NCT04162665 NCT03618758 NCT02730546	PMID 42823414 Nature communications, 2026 · High match PMID 42795931 Journal of clinical medicine, 2026 · High match PMID 42759981 Journal for immunotherapy of cancer, 2026 · High match
6	Yelena Y Janjigian Memorial Sloan Kettering Cancer Center	3	NCT04510285 NCT02954536 NCT02726399	PMID 42900867 JCO oncology practice, 2026 · High match PMID 42830450 The oncologist, 2026 · High match PMID 42319591 Annals of surgical oncology, 2026 · High match
7	Lin Shen Peking University Cancer Hospital & Institute	2	NCT04923932 NCT03472365	PMID 42583940 Journal of comparative effectiveness research, 2026 · High match PMID 42542421 Science bulletin, 2026 · High match PMID 42525321 Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2026 · High match
8	Kohei Shitara National Cancer Center Hospital East	2	NCT07529613 NCT03609359	PMID 42981428 Science translational medicine, 2026 · High match PMID 42976418 ESMO open, 2026 · High match PMID 42973799 Frontiers in oncology, 2026 · High match
9	Zhenggang Zhu Ruijin Hospital	2	NCT03636893 NCT03013010	PMID 42636892 Journal of controlled release : official journal of the Controlled Release Society, 2026 · High match
10	Min-Hee Ryu Asan Medical Center	2	NCT04309578 NCT03707028	PMID 42944820 Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2026 · High match PMID 42845257 Journal of gastric cancer, 2026 · High match PMID 42748509 ESMO open, 2026 · High match

How to read this

Sites are counted from the facility lists on the registry record, with spelling variants merged. “Listed on the trial” means the registry shows the site as a location; it is not a count of patients enrolled. The method, the formula and the published tests.

Want this for your own protocol or your CRO's list?

Leave your indication and the CRO's names. We reply by email with each one checked against these records.